Clinical importance of non‐genetic and genetic cytochrome P450 function tests in liver disease
Clinical importance of non‐genetic and genetic cytochrome P450 function tests in liver disease
复制标题
非遗传性和遗传性细胞色素 P450 功能检测在肝病中的临床重要性
DOI：
10.1046/j.1365-2710.1998.00135.x
复制
发表时间：
1998
影响因子：
2
通讯作者：
E. Tanaka
中科院分区：
文献类型：
--
作者：
E. Tanaka
肝脏疾病与通过氧化生物转化代谢的药物的代谢能力降低有关。肝微粒体中的三个细胞色素P450 （P450或CYP）基因家族（cyp1， CYP2和CYP3）似乎负责发生的大部分药物代谢。负责碎片喹/sparteine （CYP2D6）代谢和S -甲苯妥英（CYP2C19）代谢的cypps的遗传多态性已被很好地记录，但关于肝病中每种亚型的损害的信息仍然有限。肝P450功能检查有两种。一类为非基因P450功能检测（CYP1A2、2A6、2C9/10、2E1和3A3/4），探测药物包括：由CYP1A2催化的咖啡因、由CYP2A6催化的香豆素、由CYP2C6催化的苯并酮、由CYP2E1催化的氯唑酮、由CYP3A3/4催化的硝苯地平、红霉素和利多卡因。第二类基因P450功能测试（CYP2C19和CYP2D6）涉及探针药物，如由CYP2C19催化的S‐甲苯妥英，以及由CYP2D6催化的碎片喹和斯巴达丁。用于肝病患者非遗传性P450功能测试的探针药物的代谢分为两类：减少（CYP1A2, CYP2C， 2E1和3A）和不变（CYP2C）。在遗传P450功能测试中，在肝病患者中，贫代谢物（PMs）的抑制程度似乎低于广泛代谢物（EMs）。很少有关于用于肝脏疾病P450基因功能检测的探针药物代谢变化的报道。本文就这一问题作一综述
Liver disease is associated with reduced metabolic capacity for drugs that are metabolized by oxidative biotransformation. Three cytochrome P450 (P450 or CYP) gene families in liver microsomes (CYP 1, CYP2 and CYP3) appear to be responsible for much of the drug metabolism that takes place. The genetic polymorphism of the CYPs responsible for debrisoquine/sparteine (CYP2D6) metabolism and S‐mephenytoin (CYP2C19) metabolism has been well documented, but information on the impairment of each isoform in liver disease is still limited. There are two types of hepatic P450 function tests. One type consists of non‐genetic P450 function tests (CYP1A2, 2A6, 2C9/10, 2E1 and 3A3/4), and probe drugs include caffeine, catalysed by CYP1A2, coumarin by CYP2A6, phenytoin by CYP2C6, chlorzoxazone by CYP2E1, and nifedipine, erythromycin and lidocaine by CYP3A3/4. The second type of genetic P450 function tests (CYP2C19 and CYP2D6) involves probe drugs such as S‐mephenytoin, catalysed by CYP2C19, and debrisoquine and sparteine, catalysed by CYP2D6. The metabolism of the probe drugs used in non‐genetic P450 function tests in patients with liver disease falls into two categories: reduced (CYP1A2, CYP2C, 2E1 and 3A) and unchanged (CYP2C). In genetic P450 function tests there seems to be a lesser degree of inhibition in poor metabolizers (PMs) than extensive metabolizers (EMs) among patients with liver disease. There have been very few reports on changes in metabolism of the probe drugs used in genetic P450 function tests in liver disease. In this paper the subject is reviewed
登录
查看更多内容
DOI：
--
发表时间：
1994-07
期刊：
The Journal of pharmacology and experimental therapeutics
影响因子：
--
作者：
T. Shimada;H. Yamazaki;M. Mimura;Y. Inui;F. Guengerich
通讯作者：
T. Shimada;H. Yamazaki;M. Mimura;Y. Inui;F. Guengerich
DOI：
--
发表时间：
1987-03
期刊：
Drug metabolism and disposition: the biological fate of chemicals
影响因子：
--
作者：
M. Campbell;D. Grant;T. Inaba;W. Kalow
通讯作者：
M. Campbell;D. Grant;T. Inaba;W. Kalow
DOI：
10.1073/pnas.86.20.7696
发表时间：
1989-10-01
影响因子：
11.1
作者：
BUTLER, MA;IWASAKI, M;KADLUBAR, FF
通讯作者：
KADLUBAR, FF
药物遗传学：优化治疗效率的实验室工具。
影响因子：
9.3
作者：
Linder,MW;Prough,RA;ValdesJr,R
通讯作者：
ValdesJr,R
细胞色素 P4502E1 在氯唑沙宗 6-羟基化中的选择性。
DOI：
--
发表时间：
1995
期刊：
Drug metabolism and disposition: the biological fate of chemicals.
影响因子：
--
作者：
Yamazaki,H;Guo,Z;Guengerich,FP
通讯作者：
Guengerich,FP